276 related articles for article (PubMed ID: 20455894)
1. Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women.
Lebbe M; Hubinont C; Bernard P; Maiter D
Clin Endocrinol (Oxf); 2010 Aug; 73(2):236-42. PubMed ID: 20455894
[TBL] [Abstract][Full Text] [Related]
2. Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation.
Auriemma RS; Perone Y; Di Sarno A; Grasso LF; Guerra E; Gasperi M; Pivonello R; Colao A
J Clin Endocrinol Metab; 2013 Jan; 98(1):372-9. PubMed ID: 23162092
[TBL] [Abstract][Full Text] [Related]
3. Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study.
Colao A; Abs R; Bárcena DG; Chanson P; Paulus W; Kleinberg DL
Clin Endocrinol (Oxf); 2008 Jan; 68(1):66-71. PubMed ID: 17760883
[TBL] [Abstract][Full Text] [Related]
4. Prolactinomas and pregnancy.
Molitch ME
Clin Endocrinol (Oxf); 2010 Aug; 73(2):147-8. PubMed ID: 20550542
[No Abstract] [Full Text] [Related]
5. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas.
Ono M; Miki N; Amano K; Kawamata T; Seki T; Makino R; Takano K; Izumi S; Okada Y; Hori T
J Clin Endocrinol Metab; 2010 Jun; 95(6):2672-9. PubMed ID: 20357175
[TBL] [Abstract][Full Text] [Related]
6. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
[TBL] [Abstract][Full Text] [Related]
7. Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study.
Nachtigall LB; Valassi E; Lo J; McCarty D; Passeri J; Biller BM; Miller KK; Utz A; Grinspoon S; Lawson EA; Klibanski A
Clin Endocrinol (Oxf); 2010 Jan; 72(1):53-8. PubMed ID: 19508591
[TBL] [Abstract][Full Text] [Related]
8. Prolactinoma and pregnancy: From the wish of conception to lactation.
Maiter D
Ann Endocrinol (Paris); 2016 Jun; 77(2):128-34. PubMed ID: 27130071
[TBL] [Abstract][Full Text] [Related]
9. High dose cabergoline therapy for a resistant macroprolactinoma during pregnancy.
Banerjee A; Wynne K; Tan T; Hatfield EC; Martin NM; Williamson C; Meeran K
Clin Endocrinol (Oxf); 2009 May; 70(5):812-3. PubMed ID: 18803677
[No Abstract] [Full Text] [Related]
10. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy.
Kharlip J; Salvatori R; Yenokyan G; Wand GS
J Clin Endocrinol Metab; 2009 Jul; 94(7):2428-36. PubMed ID: 19336508
[TBL] [Abstract][Full Text] [Related]
11. Pregnancy and tumor outcomes in infertile women with macroprolactinoma on cabergoline therapy.
Rastogi A; Bhadada SK; Bhansali A
Gynecol Endocrinol; 2017 Apr; 33(4):270-273. PubMed ID: 27908214
[TBL] [Abstract][Full Text] [Related]
12. Cabergoline treatment of pregnant women with macroprolactinomas.
Laloi-Michelin M; Ciraru-Vigneron N; Meas T
Int J Gynaecol Obstet; 2007 Oct; 99(1):61-2. PubMed ID: 17602689
[No Abstract] [Full Text] [Related]
13. Pregnancy and Tumor Outcomes in Women with Prolactinoma.
Araujo B; Belo S; Carvalho D
Exp Clin Endocrinol Diabetes; 2017 Nov; 125(10):642-648. PubMed ID: 28704852
[No Abstract] [Full Text] [Related]
14. Secondary deterioration of visual field during cabergoline treatment for macroprolactinoma.
Raverot G; Jacob M; Jouanneau E; Delemer B; Vighetto A; Pugeat M; Borson-Chazot F
Clin Endocrinol (Oxf); 2009 Apr; 70(4):588-92. PubMed ID: 18673461
[TBL] [Abstract][Full Text] [Related]
15. Prolactinomas, cabergoline, and pregnancy.
Glezer A; Bronstein MD
Endocrine; 2014 Sep; 47(1):64-9. PubMed ID: 24985062
[TBL] [Abstract][Full Text] [Related]
16. Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.
Vroonen L; Lancellotti P; Garcia MT; Dulgheru R; Rubio-Almanza M; Maiga I; Magne J; Petrossians P; Auriemma R; Daly AF; Beckers A
Endocrine; 2017 Jan; 55(1):239-245. PubMed ID: 27709470
[TBL] [Abstract][Full Text] [Related]
17. Prolactinoma in pregnancy.
Molitch ME
Best Pract Res Clin Endocrinol Metab; 2011 Dec; 25(6):885-96. PubMed ID: 22115164
[TBL] [Abstract][Full Text] [Related]
18. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine.
Delgrange E; Maiter D; Donckier J
Eur J Endocrinol; 1996 Apr; 134(4):454-6. PubMed ID: 8640297
[TBL] [Abstract][Full Text] [Related]
19. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment.
Elenkova A; Shabani R; Kalinov K; Zacharieva S
Eur J Endocrinol; 2012 Jul; 167(1):17-25. PubMed ID: 22511808
[TBL] [Abstract][Full Text] [Related]
20. Cabergoline therapy for macroprolactinoma during pregnancy: a case report.
Shahzad H; Sheikh A; Sheikh L
BMC Res Notes; 2012 Oct; 5():606. PubMed ID: 23110890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]